Newsero
» Results Of The APPRAISE-I Dose Guiding Trial ...
News
Results Of The APPRAISE-I Dose Guiding Trial ...
While the results of the study did not show a statistically significant difference in ischemic events among any of the four doses of apixaban evaluated, trends emerged that support further study, according to researchers at the Duke Clinical Research Institute. Apixaban targets the activity of Factor Xa, one of several enzymes involved in process of blood coagulation.
Published in: Procedures and Therapies
While the results of the study did not show a statistically significant difference in ischemic events among any of the four doses of apixaban evaluated, trends emerged that support further study, according to researchers at the Duke Clinical Research Institute. Apixaban targets the activity of Factor Xa, one of several enzymes involved in process of blood coagulation.
Published in: Procedures and Therapies
© 2008 newsero.com 